Evidence map›Paper›PMID 40448114›Full record

ArticleCell communication and signaling : CCS2025

MicroRNA-371-373 cluster extracellular vesicle-based communication in testicular germ cell tumors.

Nuno Tiago Tavares, Catarina Lourenço, Vera Constâncio, Fernanda Fernandes-Pontes, Diana Fonseca, Rui Silva-Santos, Isaac Braga, Joaquina Maurício, Rui Henrique, Michelle Liu and 4 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nuno Tiago TavaresCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
Catarina LourençoCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
Vera ConstâncioCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
Fernanda Fernandes-PontesCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
Diana FonsecaCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
Rui Silva-SantosDepartment of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, 4200-072, Portugal.
Isaac BragaDepartment of Urology, Urology Clinic, Portuguese Oncology Institute of Porto (IPO Porto), Porto, 4200-072, Portugal.
Joaquina MaurícioDepartment of Medical Oncology, Urology Clinic, Portuguese Oncology Institute of Porto (IPO Porto), Porto, 4200-072, Portugal.
Rui HenriqueCancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
Michelle LiuDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Robert S WeissDepartment of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Aditya BagrodiaDepartment of Urology, University of California San Diego, San Diego, CA, USA.
Carmen Jerónimo *Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal.
João Lobo *Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / CI-IPOP@RISE Health Research Network - Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, 4200-072, Portugal. joaomachadolobo@gmail.com.

Funding

Fundação para a Ciência e a Tecnologia 2021.06731.BDFundação para a Ciência e a Tecnologia 2022.09566.BDmiREpiTestis PI190-CI-IPOP-23-2023
6 · The paper itself

Abstract

Testicular germ cell tumors (TGCTs) represent the most common type of cancer in young adults. The cluster of microRNAs 371-373 is highly upregulated in TGCTs, and detection of miR-371a-3p specifically is currently being developed for clinical implementation as a sensitive and specific biomarker for TGCT, except for teratoma. Extracellular vesicles (EVs) are nano-sized particles used for cell communication, being increasingly regarded as potential sources of cancer biomarkers. Thus, the aim of this study was to characterize EVs from a wide range of TGCT samples, including cell lines, tissue explants and matched plasma samples from patients and healthy donors, and then use these samples to assess microRNA expression (miR-371-373 cluster and let-7e). TGCT-derived EVs were successfully isolated and characterized according to MISEV guidelines. TGCT cell lines showed different levels of EV-derived miR-371-373 cluster and let-7e. Upon differentiation of NT2 cells with ATRA, both cellular and EV-derived miR-371-373 cluster were downregulated, whereas let-7e was upregulated. TGCT patient samples presented high levels of EV-derived miR-371-373, except for the teratoma samples. We conclude that a significant portion of the circulating miR-371-373 cluster used as a TGCT biomarker in the clinic is secreted into EVs, and that this cluster and the let-7 family of microRNAs may be related with TGCT intercellular communication and differentiation.

Indexed as

Cell CommunicationExtracellular VesiclesMicroRNAsNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAdultCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMIRN371 microRNA, humanMIRN373 microRNA, human

Identifiers

PMID40448114
PMCPMC12124061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.